PHARMACOLOGICAL BLOCKAGE OF SELECTIVE CANNABINOID-1 RECEPTOR

选择性大麻素 1 受体的药理学阻断

• 批准号: 7562466
• 负责人: ELIZABETH PARKS
• 金额: $ 2.68万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562466
• 关键词: Alcohols; Body Weight decreased; Cannabinoids; Computer Retrieval of Information on Scientific Projects Database; Condition; Development; Diabetes Mellitus; Drug usage; Fatty acid glycerol esters; Funding; Grant; Human; Individual; Infusion procedures; Institution; Lipoproteins; Liver; Measures; Obesity; Pilot Projects; Protocols documentation; Relative (related person); Research; Research Personnel; Resources; Risk Factors; Source; Triglycerides; United States National Institutes of Health; design; insulin sensitivity; nonalcoholic steatohepatitis; receptor; rimonabant; stable isotope

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A primary aim of this project is to study the effect of Rimonabant, a drug used for weight loss in humans, in reducing liver fat, a condition called NASH, nonalcoholic steatohepatitis, found in individuals who consume little or no alcohol. Obesity and diabetes are the two strongest risk factors for the development of NASH in humans. This pilot study has been designed to 1) allow changes in insulin sensitivity that can occur with weight loss, 2) demonstrate our ability to perform the stable isotope infusion protocols, and 3) measure the relative sources of fats (triglycerides) that are secreted in lipoproteins and stored in the liver in NASH with Rimonabant.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目的主要目的是研究利莫那班（一种用于人类减肥的药物）在减少肝脏脂肪方面的作用，这种情况称为NASH，非酒精性脂肪性肝炎，在很少或不饮酒的人中发现。 肥胖和糖尿病是人类NASH发展的两个最强风险因素。这项初步研究的目的是：1）允许体重减轻时可能发生的胰岛素敏感性变化，2）证明我们执行稳定同位素输注方案的能力，3）测量在利莫那班治疗NASH时脂蛋白中分泌并储存在肝脏中的脂肪（甘油三酯）的相对来源。